Site search

Clear filter
2855 results for '' found
Stereotactic ablative body radiation therapy with Nodal Irradiation for ProstatE canceR (ACTRN12625000259448)
Stereotactic ablative body radiation therapy with Nodal Irradiation for ProstatE canceR (ACTRN12625000259448)
/
Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with
/
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or
/
Sugammadex, neostigmine and postoperative pulmonary complications (the SNaPP Study) (ACTRN12623000394640)
/
Staphylococcus aureus Network Adaptive Platform trial (SNAP) (NCT05137119)
Staphylococcus aureus Network Adaptive Platform trial (SNAP) (NCT05137119)
/
SMITE: Superiority of Migraine Inpatient Treatment with Eptinezumab (ACTRN12621001616864)
SMITE: Superiority of Migraine Inpatient Treatment with Eptinezumab (ACTRN12621001616864)
/
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera (NCT05499013)
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera (NCT05499013)
/
A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) (NCT02821013)
/
Switching patients from intravenous to subcutaneous infliximab in inflammatory bowel disease (ACTRN12621001498886)
Switching patients from intravenous to subcutaneous infliximab in inflammatory bowel disease (ACTRN12621001498886)
/
A randomised double-blind placebo-controlled trial of topical sirolimus in chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients (NCT05860881)
/
22 23 24 25 26